KRAS G12V特异性T细胞受体治疗恶性肿瘤的临床前研究

程晓静,蒋栋,张连海,王江华,李雅真,翟佳慧,闫宝琪,张露露,谢兴旺,李子禹,季加孚

Preclinical study of T cell receptor specifically reactive with KRAS G12V mutation in the treatment of malignant tumors

Xiao-jing CHENG,Dong JIANG,Lian-hai ZHANG,Jiang-hua WANG,Ya-zhen LI,Jia-hui ZHAI,Bao-qi YAN,Lu-lu ZHANG,Xing-wang XIE,Zi-yu LI,Jia-fu JI

图2 KAV11-01和TK34 TCR亲和力及表达模式的比较

Figure 2 Comparison of affinity and expression patterns between KAV11-01 and TK34 TCR A, relative activation level of TCR+ Jurkat cells after co-incubation with T2 cells loaded with peptides, which were tested from 10-5 to 10-10mol/L and measured by flow cytometry; B, the affinity of KVA11-01 and TK34 for targeting antigen was calculated, based on the above results; C, transduction efficiencies of KAV11-01 and TK34 TCRs were analyzed by multi-staining cells with anti-CD3, anti-CD4, anti-CD8, and anti-murine TCRβ chain constant region antibody. Abbreviations as in Figure 1.